The global multiomics market accounted for USD 2.40 billion in 2023 and is expected to reach USD 11.61 billion by 2034 with a CAGR of 15.41% during the forecast period 2024-2034. The factors that will propel the market's growth include the decreasing costs of omics technologies, the growing government support and funding, the growing need for personalized medicine, and collaborative initiatives and funding support.
Governments, universities, and commercial businesses are making investments in cooperative projects and providing financial assistance for multiomics research. These programs are designed to promote multidisciplinary cooperation, standardize methods for data exchange and analysis, and aid in the creation of cutting-edge multiomics technologies and techniques. For instance, Thermo Fisher Scientific stated in January 2024 that it was expanding its molecular diagnostics capabilities by acquiring Mesa Biotech, Inc., a point-of-care molecular diagnostic company.
By type, the bulk multiomics segment accounted for the highest revenue-grossing segment in the global multiomics market in 2023 owing to the rapid adoption of multiomic approaches in pharmaceutical research and development, personalized medicine, and precision agriculture, fueled by the need for comprehensive biological insights and targeted solutions. For instance, Illumina launched the NovaSeq X, a revolutionary sequencing platform with enhanced speed and scalability for large-scale genomics projects, in February 2024. Additionally, the single-cell multiomics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for high-resolution, single-cell analysis techniques, which offer unparalleled insights into cellular heterogeneity, disease mechanisms, and therapeutic targets, driving advancements in biomedical research and personalized medicine.
By platform, the genomics segment accounted for the highest revenue-grossing segment in the global multiomics market in 2023 owing to the wide-ranging applications across various fields such as clinical diagnostics, drug discovery, agriculture, and research, coupled with continuous advancements in sequencing technologies and data analysis tools, driving robust growth in genomic research and implementation. For instance, in December 2023, Agilent Technologies announced the acquisition of Resolution Bioscience, Inc., a producer of liquid biopsy assays for cancer diagnostics, to improve its position in the oncology industry. Additionally, the metabolomics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of metabolites as key regulators of biological processes, coupled with advancements in analytical techniques such as mass spectrometry and nuclear magnetic resonance spectroscopy, enabling comprehensive profiling of metabolites for biomarker discovery, disease diagnosis, and personalized medicine.
By application, the cell biology segment accounted for the highest revenue-grossing segment in the global multiomics market in 2023 owing to the growing demand for understanding cellular functions and interactions at a molecular level, driving the adoption of multiomic approaches to unravel complex biological pathways and mechanisms underlying diseases, drug responses, and cellular behavior. For instance, in January 2024, Qiagen announced the release of the QIAseq Targeted RNA Panels for single-cell RNA sequencing, allowing researchers to investigate gene expression at the single-cell level. Additionally, the oncology segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of cancer worldwide, coupled with the demand for personalized and targeted therapies, driving the adoption of multiomic approaches to elucidate tumor heterogeneity, identify biomarkers for early detection, prognosis, and treatment response prediction, and accelerate drug development in oncology.
By end-user, the academic and research institutes segment accounted for the highest revenue-grossing segment in the global multiomics market in 2023 owing to the significant government funding, collaboration opportunities, and academic research initiatives driving the adoption of multiomic technologies for advancing scientific understanding, disease research, and drug discovery efforts. For instance, in November 2023, PerkinElmer announced the acquisition of BioLegend, Inc., a provider of antibodies and immunology research reagents, in order to broaden its line of life science products. Additionally, the pharmaceutical and biotechnology company segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investment in drug discovery and development, coupled with the demand for precision medicine and personalized therapies, driving the adoption of multiomic approaches to accelerate target identification, biomarker discovery, and drug candidate optimization.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established pharmaceutical and biotechnology industries, strong research infrastructure, favorable government initiatives, and increasing adoption of multiomic technologies in precision medicine and healthcare applications. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology and pharmaceutical sectors, increasing investment in research and development, growing healthcare infrastructure, and rising adoption of multiomic technologies in emerging economies such as China and India. For instance, in February 2024, Bio-Rad Laboratories announced the release of the Bio-Plex Pro Human Immunotherapy Panel 1, a multiplex assay for detecting cytokines and chemokines linked with immunotherapy responses.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Governments, universities, and commercial businesses are making investments in cooperative projects and providing financial assistance for multiomics research. These programs are designed to promote multidisciplinary cooperation, standardize methods for data exchange and analysis, and aid in the creation of cutting-edge multiomics technologies and techniques. For instance, Thermo Fisher Scientific stated in January 2024 that it was expanding its molecular diagnostics capabilities by acquiring Mesa Biotech, Inc., a point-of-care molecular diagnostic company.
By type, the bulk multiomics segment accounted for the highest revenue-grossing segment in the global multiomics market in 2023 owing to the rapid adoption of multiomic approaches in pharmaceutical research and development, personalized medicine, and precision agriculture, fueled by the need for comprehensive biological insights and targeted solutions. For instance, Illumina launched the NovaSeq X, a revolutionary sequencing platform with enhanced speed and scalability for large-scale genomics projects, in February 2024. Additionally, the single-cell multiomics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for high-resolution, single-cell analysis techniques, which offer unparalleled insights into cellular heterogeneity, disease mechanisms, and therapeutic targets, driving advancements in biomedical research and personalized medicine.
By platform, the genomics segment accounted for the highest revenue-grossing segment in the global multiomics market in 2023 owing to the wide-ranging applications across various fields such as clinical diagnostics, drug discovery, agriculture, and research, coupled with continuous advancements in sequencing technologies and data analysis tools, driving robust growth in genomic research and implementation. For instance, in December 2023, Agilent Technologies announced the acquisition of Resolution Bioscience, Inc., a producer of liquid biopsy assays for cancer diagnostics, to improve its position in the oncology industry. Additionally, the metabolomics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of metabolites as key regulators of biological processes, coupled with advancements in analytical techniques such as mass spectrometry and nuclear magnetic resonance spectroscopy, enabling comprehensive profiling of metabolites for biomarker discovery, disease diagnosis, and personalized medicine.
By application, the cell biology segment accounted for the highest revenue-grossing segment in the global multiomics market in 2023 owing to the growing demand for understanding cellular functions and interactions at a molecular level, driving the adoption of multiomic approaches to unravel complex biological pathways and mechanisms underlying diseases, drug responses, and cellular behavior. For instance, in January 2024, Qiagen announced the release of the QIAseq Targeted RNA Panels for single-cell RNA sequencing, allowing researchers to investigate gene expression at the single-cell level. Additionally, the oncology segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of cancer worldwide, coupled with the demand for personalized and targeted therapies, driving the adoption of multiomic approaches to elucidate tumor heterogeneity, identify biomarkers for early detection, prognosis, and treatment response prediction, and accelerate drug development in oncology.
By end-user, the academic and research institutes segment accounted for the highest revenue-grossing segment in the global multiomics market in 2023 owing to the significant government funding, collaboration opportunities, and academic research initiatives driving the adoption of multiomic technologies for advancing scientific understanding, disease research, and drug discovery efforts. For instance, in November 2023, PerkinElmer announced the acquisition of BioLegend, Inc., a provider of antibodies and immunology research reagents, in order to broaden its line of life science products. Additionally, the pharmaceutical and biotechnology company segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investment in drug discovery and development, coupled with the demand for precision medicine and personalized therapies, driving the adoption of multiomic approaches to accelerate target identification, biomarker discovery, and drug candidate optimization.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established pharmaceutical and biotechnology industries, strong research infrastructure, favorable government initiatives, and increasing adoption of multiomic technologies in precision medicine and healthcare applications. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology and pharmaceutical sectors, increasing investment in research and development, growing healthcare infrastructure, and rising adoption of multiomic technologies in emerging economies such as China and India. For instance, in February 2024, Bio-Rad Laboratories announced the release of the Bio-Plex Pro Human Immunotherapy Panel 1, a multiplex assay for detecting cytokines and chemokines linked with immunotherapy responses.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Platform, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Multiomics Market Report 2023 - 2034
Multiomics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Single-cell Multiomics
- Bulk Multiomics
Multiomics Market Analysis & Forecast by Platform 2023 - 2034 (Revenue USD Bn)
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
Multiomics Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cell Biology
- Oncology
- Neurology
- Immunology
Multiomics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Multiomics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Multiomics Market: Type Estimates & Trend Analysis
8. Multiomics Market: Platform Estimates & Trend Analysis
9. Multiomics Market: Application Estimates & Trend Analysis
10. Multiomics Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Multiomics Market
13. Europe Global Multiomics Market
14. Asia Pacific Global Multiomics Market
15. Latin America Global Multiomics Market
16. MEA Global Multiomics Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Agilent Technologies Inc.
- Qiagen N.V.
- PerkinElmer Inc.
- Bio-Rad Laboratories Inc.
- Bruker Corporation
- Waters Corporation
- Pacific Biosciences of California Inc.
- Oxford Nanopore Technologies Ltd.
- 10x Genomics Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Eurofins Scientific
- Merck KGaA.
